Lineage Cell Therapeutics Inc’s market performance has been unstable in recent times. The company’s stock hit a 1-year high of $1.61 on 03/28/24 and a low of $0.77 for the same time frame on 08/14/24.
52-week price history of LCTX Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Lineage Cell Therapeutics Inc’s current trading price is -47.51% away from its 52-week high, while its distance from the 52-week low is 10.25%. The stock’s price range during this period has spanned from $0.77 to $1.61. In the Healthcare sector, the Lineage Cell Therapeutics Inc’s shares surpassed a trading volume of approximately 0.78 million for the day, which was noticeably higher compared to the average daily volume of 9.0.48 million over the past three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Market Capitalization and Financial Performance: An In-Depth Look
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -16.33% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 159.59M and boasts a workforce of 75 employees.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9346, with a change in price of -0.2349. Similarly, Lineage Cell Therapeutics Inc recorded 669,304 in trading volume during the last 100 days, posting a change of -21.75%.
Examining LCTX’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.03.
LCTX Stock Stochastic Average
Today’s raw stochastic average for Lineage Cell Therapeutics Inc over the last 50 days is 28.74%.This indicates a decrease from the raw stochastic average of the past 20 days, which was 34.23%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 24.65% and 23.30%, respectively.
LCTX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a loss of -22.47%.However, over the last six months, we can see a stronger performance of -40.06%. Over the last 30 days, the price of LCTX has leaped by -2.32%. And in the last five days, it has fallen by -5.99%.
